Cynvenio Biosystems, Inc., a Westlake Village, California-based developer of LiquidBiopsy technology for the genomic analysis of tumor cells from whole blood in support of cancer precision medicine strategies, completed a $25.5m Series B equity financing.
The round was led by Livzon Pharmaceutical Group, Inc. a diversified drug, diagnostics and healthcare company based in Zhuhai, P.R. China. Other investors included Greenwoods Private Equity Funds (Shanghai) and Syno Capital (New York), among others.
The company intends to use the funds to advance for the clinical development and commercialization programs.
Led by André de Fusco, CEO, Cynvenio develops LiquidBiopsy technology that provides access to diverse populations of rare cancer cells in whole blood. The technology, which includes automated instrumentation, consumables/reagents, patients sample kits, and bioinformatics for sequencing rare cell populations, powers the simultaneous analyses of three distinct templates from a single blood sample – DNA from circulating tumor cells (ctcDNA), circulating tumor DNA (ctDNA) and germline DNA – to provide auditable genomic readouts.